Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies

Descripción del proyecto

Diagnóstico y tratamiento rápidos de enfermedades raras

Hay más de siete mil enfermedades raras conocidas, dolencias que afectan a no más de una de cada dos mil personas. En su conjunto, estas enfermedades que padecen hasta treinta y seis millones de personas en toda la Unión Europea (UE) y que afectarán a una de cada diecisiete personas a lo largo de su vida, a menudo son enfermedades crónicas multiorgánicas graves que pueden causar daño y degeneración permanente de los órganos. Por lo general, los pacientes afrontan un viaje arduo hacia un diagnóstico adecuado. En este contexto, el proyecto SCREEN4CARE, financiado con fondos europeos, tiene como objetivo acortar el tiempo de diagnóstico y tratamiento de los pacientes con enfermedades raras. En el proyecto, que reúne a treinta y cinco socios en un consorcio público-privado internacional, se utilizará una estrategia múltiple que incluye el cribado genético de recién nacidos y algoritmos basados en inteligencia artificial (IA) para identificar a los pacientes en el estadio incipiente de una enfermedad.

Objetivo

In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/) 30 million persons, 3,5-6% of the general population, are affected by one of the 6,172 different rare diseases (RDs) of which 72% are genetic and 70% affect children. The path to diagnosis for people suffering from a RD is burdensome, often severely delayed by a diagnostic odyssey. Lack of timely diagnosis affects disease management, family planning, identification of potential beneficial treatments and / or clinical trials. This unacceptable situation does not meet the concept of equity for EU citizens, and requires rapid, structured, and cost-effective corrective actions. The Screen4Care (S4C) consortium will leverage the genomic and digital advent to develop and pilot genetic NBS and AI-guided symptom recognition algorithms, while accounting for all relevant legal, regulatory and ethical considerations. S4C aims to harmonize the results of existing efforts in a horizon scan, by looking at the totality of the available data resources, diagnostic algorithms, and other initiatives with similar ultimate goals.
The genetic NBS will interrogate 1) currently treatable RDs (TREAT-map gene panel), 2) actionable RDs (ACT-map gene panel) in 18.000 new-borns in 3 EU countries (D, It, and Cz). Further, S4C will offer whole genome sequencing (WGS) to early symptomatic babies, tested negatively during panel-based NBS to identify known NBS-escaped RDs and novel genes/phenotypes.
S4C will also provide two digital diagnosis support systems for RD on the basis of features and symptom complexes: 1) federated ML- and literature-evidence-based algorithm for continuous and automated screening of EHR and 2) meta symptom checker with virtual clinics for patients and HCP offering the possibility of increased accuracy of diagnosis and ongoing supports. Our ambitious goal is to evaluate the validity of our multi-pronged approach to shorten the time to diagnosis for all patients affect by RDs, improve value-based healthcare resource utilization, and hopefully reduce the suffering of millions of European citizens.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

UNIVERSITA DEGLI STUDI DI FERRARA
Aportación neta de la UEn
€ 691 786,00
Dirección
VIA ARIOSTO 35
44121 Ferrara
Italia

Ver en el mapa

Región
Nord-Est Emilia-Romagna Ferrara
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 404 286,25

Participantes (40)